Pfizer (PFE) Stock Price Forecast for 2025, 2026, 2027–2030, 2040 and Beyond

Pfizer (#PFE) stocks have garnered considerable attention from investors thanks to their promising upside potential and highly active market conditions. Amid global economic volatility and new healthcare challenges, #PFE offers a compelling option for both short- and long-term investments.

Forecasts for the coming years show a wide range of potential prices, reflecting possible fluctuations and yield increases. Analyzing current trends and seasonal movements presents a unique opportunity to identify optimal market entry points and assess investment risk. 

This article provides an in-depth analysis of Pfizer stocks, helping you grasp the intricacies of the market and empowering you to make more informed trading decisions.

The article covers the following subjects:

Major Takeaways

• The PFE stock price is trading at $24.39 as of 17.06.2025.
• The PFE price reached its all-time high of $61.25 on 16.12.2021. The stock’s all-time low of $0.43 was recorded on 04.10.1974.
• In 2024, the company implemented strategic initiatives to optimize its product lineup and expand its global footprint.
• The PFE stock is traded on the New York Stock Exchange (NYSE) under the ticker symbol #PFE, making it accessible to a wide range of investors.
• The company maintains stable operating profit by actively investing in research and innovation.
• Free cash flow makes it possible to finance new projects and maintain a proper dividend policy.
• In 2025, Pfizer shares are trading at around $26, reflecting stabilization efforts rather than revenue growth or a strengthening of its global position. Annual forecasts point to a wide range of possible scenarios, with no clear signs of a reversal or robust recovery.

Pfizer (PFE) Real-Time Market Status

The current Pfizer (#PFE) stock price is $24.39 as of 17.06.2025.

Investors should monitor key metrics that help assess the financial strength of a company, upside potential, and stock liquidity. For example, market capitalization indicates the overall value of the company, while trading volume reflects market activity. The P/E ratio assesses stock profitability, and the price change over the last 12 months helps to assess the stock’s performance. Additionally, dividend yield and maximum supply help gauge shares’ profitability and availability.

Metric	Value
Market cap	$132.87 billion
Trading volume	24.22 million shares
P/E ratio	16.83
All-time high	$61.25
Price change over the last 12 months	-21.76%
Dividends	$1.72 (7.44%)
Shares outstanding	5.69 billion shares

Pfizer (PFE) Stock Price Forecast for 2025 Based on Technical Analysis 

Pfizer shares continue to trade in a downtrend, remaining below the 50-day moving average (SMA), which stands at 26.51. The moving average acts as strong resistance, limiting any upward movement and confirming the prevailing bearish sentiment. The price is consolidating below the 24.00 level and may decline further if it breaches the swing lows.

The MACD indicator remains in the negative zone. The MAGD line is below the signal line, and the histogram is contracting, signaling weak bullish activity and continued downward pressure. These are signs confirming further decline.

The RSI is holding near 42, remaining in the neutral zone but leaning toward the oversold condition. This value may indicate weak bullish momentum and suggest further bearish movement.

If the current downward pressure persists, the share price may fall to around 18.40 by the end of 2025, especially if the nearest support levels are pierced.

Below are the Pfizer (#PFE) share price estimates for the next 12 months.

Month	Minimum, $	Maximum, $
June 2025	22.80	25.00
July 2025	22.10	24.20
August 2025	21.40	23.60
September 2025	20.50	22.90
October 2025	19.80	21.90
November 2025	19.00	21.10
December 2025	18.50	20.30
January 2026	18.40	19.80
February 2026	18.20	19.50
March 2026	18.00	19.20
April 2026	17.90	19.00
May 2026	17.80	18.80

Long-Term Trading Plan for PFE for 2025

In 2025, Pfizer shares are maintaining a downtrend, facing bearish pressure. Moving averages and the price performance indicate a prolonged correction, with demand remaining limited. Volatility is moderate. Therefore, one may gradually accumulate positions within a medium-term strategy.

Key resistance levels are located in the range of 25.00–26.00. One may consider short trades during pullbacks with a target of 20.00 and below. The nearest bearish target is around 18.40. This level can be reached by the end of the year if the current market structure remains unchanged.

To trade within the range between resistance and support levels, traders should focus on Price Action signals and confirmation from the RSI or MACD. New long trades can be opened only if the price breaks above 26.00, accompanied by growing volumes and a change in momentum.

Analysts’ PFE Share Price Projections for 2025

Forecasts for Pfizer’s share price in 2025 reflect analysts’ opinions on the likely price movements in the coming months. The data is provided in a monthly breakdown, highlighting the lowest, average, and highest projected values. This format enables you to compare seasonal fluctuations and assess the instrument’s potential, taking into account current market conditions and investor sentiment.

CoinCodex

Price range for 2025: $22.11–$34.64 (as of 07.06.2025).

According to CoinCodex, the Pfizer stock may shift from a consolidation phase to a notable advance by the end of the year. The forecast points to upward momentum, particularly in Q4. Prices above $30.00 in November–December may indicate renewed investor interest and a continuation of the bullish trend.

Month	Minimum, $	Average, $	Maximum, $
June	22.11	23.17	23.98
July	22.50	23.64	26.00
August	25.73	27.75	30.01
September	25.23	25.96	26.80
October	24.64	25.38	26.80
November	26.14	29.10	31.03
December	29.51	32.39	34.64

StockScan

Price range for 2025: $19.11–$27.04 (as of 07.06.2025).

StockScan predicts that the stock will likely lose ground in the second half of summer 2025, followed by a gradual recovery as autumn begins. September and November are expected to be relatively stable. The year is projected to end with moderate fluctuations and no clear direction, though the overall structure suggests attempts to break out of the sideways channel.

Month	Minimum, $	Average, $	Maximum, $
June	20.21	20.91	25.88
August	19.11	21.38	22.51
September	22.08	26.07	27.04
October	23.56	24.05	26.70
November	23.11	24.43	25.25
December	22.42	23.31	26.66

AuStockExchange

Price range for 2025: $25.63–$32.60 (as of 07.06.2025).

AuStockExchange expects Pfizer to climb steadily from June to December. In autumn, the average price is likely to exceed $28.00, reflecting a gradual recovery in demand. Notably, in October and November, the price is projected to approach a swing high. Overall, the outlook for the second half of the year is moderately optimistic.

Month	Minimum, $	Average, $	Maximum, $
June	25.63	26.98	28.33
July	25.87	27.38	28.89
August	26.31	27.78	29.25
September	26.64	28.24	29.84
October	27.22	28.87	30.51
November	28.31	29.71	31.11
December	29.55	31.8	32.60

WalletInvestor

Price range for 2025: $19.443–$22.494 (as of 07.06.2025).

WalletInvestor suggests the price may remain under pressure in the second half of 2025. The price is forecast to decline gradually from July to December, with no signs of a rebound. By October, average values may fall below $20.00, and the price movement is expected to stay muted, with sentiment largely bearish.

Month	Minimum, $	Average, $	Maximum, $
July	22.200	22.347	22.494
August	21.282	21.823	22.364
September	20.121	20.634	21.147
October	19.674	19.882	20.089
November	19.491	19.574	19.657
December	19.443	19.605	19.766

Analysts’ PFE Share Price Projections for 2026

Sustained interest in Pfizer provides a moderately positive outlook for 2026. Investors are closely watching how the healthcare sector responds to macroeconomic signals, evaluating recovery prospects, and new market opportunities.

CoinCodex

Price range for 2026: $25.00–$33.90 (as of 07.06.2025).

CoinCodex anticipates PFE to show a mixed but generally positive performance in 2026. The stock price is projected to reach a high in January and retreat to a low in October. Despite fluctuations, average values are likely to reach around $30.00, reflecting steady investor interest and room for a potential rebound by year-end.

Year	Minimum, $	Average, $	Maximum, $
2026	25.00	29.52	33.90

StockScan

Price range for 2026: $21.46–$40.37 (as of 07.06.2025).

StockScan believes the Pfizer price may accelerate by the second half of 2026. After a sluggish start, the stock is expected to gain momentum in July, with October and November marking the peak. This autumn rally may lift the price toward $40.00, pointing to strong investor engagement and increasing bullish sentiment.

Year	Minimum, $	Average, $	Maximum, $
2026	21.46	27.31	40.37

AuStockExchange

Price range for 2026: $29.55–$44.33 (as of 07.06.2025).

According to AuStockExchange, Pfizer shares will likely follow a consistent upward trajectory throughout 2026. The stock may advance gradually with minimal pullbacks, picking up pace in September. The price is expected to reach a high of $44.33 in December. The support level is predicted to form above $31.00, reinforcing a positive long-term outlook.

Year	Minimum, $	Average, $	Maximum, $
2026	29.55	34.52	44.33

Analysts’ PFE Share Price Projections for 2027

As 2027 approaches, analysts are updating their scenarios for Pfizer, factoring in the impact of macroeconomic and industry factors. Forecasts vary depending on each platform’s approach. Below is a compilation of estimates from leading sources reflecting possible scenarios for the year.

CoinCodex

Price range for 2027: $15.69–$30.53 (as of 07.06.2025).

According to CoinCodex, Pfizer stock is expected to trade in a pronounced downtrend in 2027. The price is expected to reach a high in January, then drop steadily, hitting a low in December. Average values also drift lower throughout the year.

Year	Minimum, $	Average, $	Maximum, $
2027	15.69	22.61	30.53

StockScan

Price range for 2027: $29.60–$50.54 (as of 07.06.2025).

StockScan suggests that 2027 may be marked by significant volatility. After a strong rally in Q1 and setting a high in April, the price may fluctuate between periods of gains and pullbacks. The average price remains above $37.00, while the widening range of price swings may reflect an unstable yet active market phase.

Year	Minimum, $	Average, $	Maximum, $
2027	29.60	40.12	50.54

AuStockExchange

Price range for 2027: $42.25–$56.90 (as of 07.06.2025).

AuStockExchange estimates that Pfizer’s price may increase within an expanding range in 2027. Projected levels shift higher compared to the previous period, with the price reaching a high of $56.90. This outlook indicates a moderately stable bullish scenario, with possible price spikes driven by external factors or corporate news.

Year	Minimum, $	Average, $	Maximum, $
2027	42.25	49.58	56.90

Analysts’ PFE Share Price Projections for 2028

Analysis resources publish estimates for Pfizer in 2028 based on technical data, seasonal trends, and fundamental industry signals. Below are forecasts from leading platforms containing targets for the minimum, average, and maximum values throughout the year.

CoinCodex

Price range for 2028: $14.82–$18.35 (as of 07.06.2025).

According to CoinCodex, the Pfizer stock is expected to trade within a relatively narrow range in 2028. The price is projected to reach a high in July and a low in November. Overall, the year is expected to be moderately volatile, with the average value holding near $16.64, suggesting a potential consolidation phase.

Year	Minimum, $	Average, $	Maximum, $
2028	14.82	16.58	18.35

StockScan

Price range for 2028: $25.96–$44.65 (as of 07.06.2025).

StockScan estimates that Pfizer’s price may fluctuate unevenly in 2028, showing a notable upturn in Q2 followed by a gradual pullback. The price is forecast to reach a high in May and a low in December. The average price may reach around $33.47, reflecting mixed expectations amid market swings.

Year	Minimum, $	Average, $	Maximum, $
2028	25.96	33.47	44.65

AuStockExchange

Price range for 2028: $55.75–$70.50 (as of 07.06.2025).

AuStockExchange predicts a clear upward trajectory for Pfizer in 2028. Both the highest and lowest prices are expected to be noticeably higher than in previous years, which may indicate Pfizer’s strengthening market position, supported by sectoral and macroeconomic factors. The trading range remains wide, with the average value exceeding $63.00.

Year	Minimum, $	Average, $	Maximum, $
2028	55.75	63.13	70.50

Analysts’ PFE Share Price Projections for 2029

Long-term scenarios for 2029 are shaped by multi-year trends and key macroeconomic factors. Various analysis platforms present their own projections, each based on their calculation models.

CoinCodex

Price range for 2029: $12.92–$20.47 (as of 07.06.2025).

According to CoinCodex, the Pfizer stock may move within a broader sideways channel in 2029. Following weak starting levels, the price is expected to reach swing lows in spring, while the end of the year may bring a moderate recovery. The average price is projected to stay near $15.23. The highest point may be hit in December.

Year	Minimum, $	Average, $	Maximum, $
2029	12.92	15.23	20.47

StockScan

Price range for 2029: $12.93–$28.06 (as of 07.06.2025).

StockScan forecasts a notable divergence between the start and end of the year in 2029. The price opens at a high in January and then gradually decreases, reaching a low in December. The average value is expected to hold around $20.99, highlighting a volatile environment and a prolonged bearish phase.

Year	Minimum, $	Average, $	Maximum, $
2029	12.93	20.99	28.06

AuStockExchange

Price range for 2029: $69.51–$85.01 (as of 07.06.2025).

AuStockExchange anticipates a period of steady recovery for Pfizer in 2029. The stock is projected to trade in a wide ascending channel, surpassing previous levels. This market structure suggests a dominance of supportive factors and the potential to reach new price targets over the long term.

Year	Minimum, $	Average, $	Maximum, $
2029	69.51	77.26	85.01

Analysts’ PFE Share Price Projections for 2030

Analysts’ forecasts for Pfizer in 2030 help outline potential stock price movements throughout the year. Forecasting methods and initial data vary across platforms, leading to differences in projected price ranges.

CoinCodex

Price range for 2030: $14.76–$20.04 (as of 07.06.2025).

CoinCodex suggests that the Pfizer stock may show a balanced performance in 2030, with prices moving within a restrained range and devoid of pronounced extremes. A modest upswing in Q1 will likely be followed by stabilization in the second half of the year. Deviations from the baseline levels are expected to remain limited, indicating a market without strong trends.

Year	Minimum, $	Average, $	Maximum, $
2030	14.76	17.38	20.04

StockScan

Price range for 2030: $2.43–$17.83 (as of 07.06.2025).

StockScan expects considerable price turbulence for Pfizer in 2030, starting moderately in Q1 before falling sharply by April. Toward the end of the year, volatility is projected to surge, with the price reaching some of the year’s lowest levels in November and December. The trading range is likely to remain exceptionally broad compared to previous years.

Year	Minimum, $	Average, $	Maximum, $
2030	2.43	11.55	17.83

AuStockExchange

Price range for 2030: $83.62–$99.60 (as of 07.06.2025).

According to AuStockExchange, the Pfizer stock may experience a major price expansion in 2030, with projected levels significantly surpassing those of prior years. The formation of a high-price zone may reflect a shift in the long-term outlook and a potential reevaluation of the company’s performance.

Year	Minimum, $	Average, $	Maximum, $
2030	83.62	91.61	99.60

Analysts’ PFE Share Price Projections until 2050

Long-term forecasts for Pfizer shares vary significantly, depending on the methodologies and strategic assumptions of different analysis platforms. Some predict substantial growth in market capitalization, while others anticipate a potential weakening of its market position over the next 15–25 years.

CoinCodex predicts that the price will trade in a range of $3.03–$3.76 in 2040, averaging $3.39. The outlook indicates limited volatility and weak trading activity. By 2050, values are expected to plummet to $1.05–$1.37, with an average price of $1.25. This scenario reflects a lack of upside potential and suggests stagnation.

AuStockExchange presents a contrasting forecast. The price is predicted to range between $200.70 and $220.54 in 2040, averaging $210.62. By 2050, the asset is projected to soar to $344.63–$365.25, with an average value of $354.94. This prediction indicates confidence in long-term growth and a significant revaluation of Pfizer’s performance.

CoinPriceForecast only provides data for 2035, projecting an average price of $39.20. The outlook points to a steady recovery driven by moderate growth. Market momentum appears balanced, with no signs of market overheating or aggressive expansion.

Year	CoinCodex, $	AuStockExchange, $	CoinPriceForecast, $
2035	–	–	39.20
2040	3.39	210.62	–
2050	1.25	354.94	–

Projections for 2050 show a broad spectrum of expectations, from gradual decline to exponential growth. This variation highlights the need to review trading strategies and track key market factors regularly. Long-term investments in Pfizer require a flexible approach that considers different scenarios, enabling a more accurate response to market changes while ensuring investment stability.

Market Sentiment for Pfizer (PFE) on Social Media

News, analyses, and social media publications shape the emotional background surrounding a company and affect market participants’ behavior. In the case of Pfizer, which operates in the pharmaceutical and biotechnology sectors, reactions to news releases can be particularly sensitive. Reports on clinical trials, regulatory decisions, or drug commercialization form opinions about the sustainability of the business model and long-term potential.

Positive news, such as the approval of new medicines, expansion into international markets, or increased revenue from flagship products, can boost investor interest. Conversely, delays in development, heightened competition, or downward revisions to forecasts can put short-term pressure on shares. Therefore, media sentiment is seen as an additional indicator of current market expectations, reflecting not price movements but reactions to the broader context.

User @tey_west notes on X (formerly Twitter) that wave D in the ABCDE pattern has finished, and the price continues to move within a long-standing 25-year channel, indicating a convergence of the EMA and Fibonacci levels. The user believes that Pfizer is a technically interesting asset with long-term potential.

User @castlehillcap suggests that the stock price should breach the $23.75 level to exit the downtrend. The analyst highlights the lack of catalysts but emphasizes the attractive dividend yield of 7% and the impact of interest rates as potential favorable factors.

Discussion around Pfizer stocks remains subdued. Users point to technical levels and a possible rebound. However, they do not expect substantial gains. Many view the stock primarily as a dividend play, focusing more on its value than its growth potential.

Market sentiment is moderate, with no signs of euphoria or panic. Investors are waiting for clear signals and are not rushing to buy. The primary focus is on technical analysis and the price responses to key levels. The asset is promising, yet there is no significant demand at this stage.

Pfizer (PFE) Price History

Pfizer reached the highest price of $61.25 on 16.12.2021. The lowest price of Pfizer was recorded on 04.10.1974 when the stock declined to $0.43.

The chart below shows the #PFE price performance over the last ten years. It is crucial to evaluate historical data to make our forecasts as accurate as possible.

Pfizer’s share price has hit several key milestones since the early 2000s:

• In 2000, the #PFE price hit a record high of about $50, bolstered by the successful launch of blockbuster drugs such as Viagra, Lipitor, and Zoloft.
• From 2004 to 2009, the #PFE price plunged to $12–$15 due to the company losing several patents and facing heightened competition. Moreover, the global financial crisis of 2008 contributed to these challenges.
• From 2013 to 2019, Pfizer’s share price stabilized in the $35–$45 range thanks to advances in oncology, vaccines, biopharmaceuticals, and a solid dividend policy.
• In 2021, the asset set an all-time high of $61 as sales of Comirnaty, a vaccine developed with BioNTech, generated record revenue for the company.
• In 2023–2025, demand for the vaccine dropped sharply, consequently reducing revenue, and the #PFE price plummeted.
• In Q1 2025, Pfizer shares traded at around $26, reflecting the company’s efforts to navigate ongoing challenges and its ability to adapt to new market conditions. Amid a highly competitive environment and slowing growth in the pharmaceutical sector, Pfizer aimed to maintain operational stability through portfolio restructuring, cost optimization, and a heightened emphasis on promising therapeutic areas. Although the market response was muted, a stable dividend policy and management’s confidence in a medium-term recovery helped sustain investor interest. Additionally, the period was marked by cautious optimism regarding new drug developments and continued research in mRNA technologies.

The Pfizer stock has historically demonstrated the capacity to recover from severe downturns, indicating future upside potential.

Pfizer (PFE) Fundamental Analysis

Fundamental analysis plays a key role in forecasting the price of any asset. It involves assessing financial data, the company’s market position, and other indicators affecting the #PFE rate.

What Factors Affect the Pfizer (PFE) Stock?

• Financials. The company’s revenues, net income, profitability, and cash flows.
• Development and market launch of new drugs. Successful clinical tests and regulatory approvals.
• Patent protection. Expiration of patents on key drugs, the emergence of generics.
• Mergers and acquisitions. Strategic deals that expand product range and distribution markets.
• Regulatory environment. Changes in healthcare legislation and policy.
• Global economic conditions. Economic crises, currency fluctuations, and geopolitical instability.
• Competition. Actions of major competitors and innovation in the industry.
• Reputational risks. Lawsuits, fines, and public opinion.
• Dividend policy. Changes in the amount and regularity of payments to shareholders.
• Investor sentiment. General trends in the stock market and investors’ attitudes to the pharmaceutical sector.

Given these factors, investors can objectively assess the prospects of the Pfizer stock and make more informed decisions.

More Facts About Pfizer (PFE)

Pfizer Inc. is a prominent American biopharmaceutical company founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York. The company develops, produces, and sells drugs and vaccines to treat various diseases. Pfizer is particularly well-known for its flagship products, such as Lipitor (atorvastatin) to lower cholesterol, Viagra (sildenafil) to address erectile dysfunction, and Prevenar, a pneumococcal vaccine.

In 2020, Pfizer, in collaboration with the German company BioNTech, developed Comirnaty, one of the first COVID-19 vaccines based on mRNA technology, which significantly boosted Pfizer’s global profile. The company is actively investing in research and development to expand its range of innovative medicines and solidify its position in the global pharmaceutical market.

Advantages and Disadvantages of Investing in Pfizer (PFE)

Pfizer is one of the largest pharmaceutical companies, producing popular and effective medications. Moreover, it adheres to a solid dividend policy, making the #PFE stock a safe investment option. However, like any other asset, #PFE carries not only benefits but also risks.

Advantages

• Stable pharmaceutical business. Wide range of high-demand drugs and vaccines.
• Dividend payouts. The yield is above the market average (~5%).
• Innovation leadership. Significant investments in R&D and breakthrough drugs (oncology, vaccines).
• Defensive asset. Demand for drugs remains strong even during crises.
• Global expansion. Operations in key pharmaceutical markets.
• Government support. Cooperation with regulators and research funding.
• Access to new technologies. Regular acquisitions of biotech companies.

Disadvantages

• Declining post-COVID revenues. Falling demand for vaccines and drugs used for COVID-19 treatment.
• Dependence on regulators. FDA approvals and patent litigation can impact revenue.
• Risk of patent expiration. Loss of exclusive rights reduces revenues (Lipitor is an example).
• High competition. Competing with other pharma giants for market and innovation.
• Long development cycle. Clinical tests can take years, and failures lead to significant losses.
• Sensitivity to macroeconomics. Drug price regulation, inflation.
• Stock fluctuations. Despite the stability of this field, the PFE price is susceptible to market trends.

Pfizer (PFE) is a resilient pharmaceutical company known for its solid dividends and opportunities for growth through innovation. However, investors should keep in mind that the stock price might be influenced by factors such as declining post-COVID earnings, upcoming patent expirations, and intense competition. Although the asset is suitable for long-term investments, it is essential to assess the associated risks thoroughly.

How We Make Forecasts

Stock prices are forecast based on three time frames

• Short-term forecasts (up to 6 months) rely on technical analysis (support/resistance levels, indicators, volumes) and news. Macroeconomic events, reports, and market reactions are taken into account.
• Medium-term forecasts (from 6 months to 3 years) include fundamental analysis (financial indicators, competitive advantages, sales trends). Macroeconomic trends, interest rates, geopolitics, and the company’s product cycle are assessed.
• Long-term forecasts (3 years or more) are focused on strategic analysis. Industry potential, innovation, growth prospects, capital management, and global factors are explored. Besides, discounted cash flow (DCF) models and multiple valuations are also used.

However, each new forecast requires adjustment to align with the latest data and evolving market conditions.

Conclusion: Is Pfizer (PFE) a Good Investment?

Pfizer is navigating the transition to a post-pandemic landscape marked by slower growth, heightened competition, and revenue pressures. Despite these challenges, the company maintains a strong market position, offering regular dividends and a commitment to long-term scientific innovation. Although the forecasts differ, the range of projections allows for a more flexible approach.

Amid uncertainty, PFE may serve as a hedge in a balanced portfolio with moderate upside potential. Further growth cannot be ruled out, but it will require patience and a strategic outlook. Pfizer is suitable for investors seeking stability rather than quick profits.

Price chart of PFE in real time mode